Care Access has acquired Instituto Brasil de Pesquisa Clínica (IBPClin), a clinical trial centre in Rio de Janeiro, Brazil, to expand its decentralised clinical trial (DCT) capabilities to Latin America.

IBPClin is one of the largest Latin American research centres.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The centre has to date carried out over 160 industry-sponsored research studies that enrolled more than 7,000 subjects across 12 states in Brazil and provides remote monitoring, telemedicine and home care assistance for patients. 

With the takeover, the IBPClin’s research team can serve Latin American patients with what previously has been US-only decentralised expertise that can bring complex research visits to patients who are interested.

Through the acquisition, difficult-to-reach, underserved and usually underrepresented population in the Latin American region will gain access to clinical trials.

Care Access has developed a clinical trial delivery model for decentralising the clinical research site and brings research to patients who are difficult to reach, by merging mobile research infrastructure, traveling clinical specialists and virtual investigators. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

This strategy has extended access to trials for varied and underserved population in the US and has attracted investment to healthcare infrastructure and enhanced the quality of care.

The company has made substantial development using Series C and Series D financing over the last year to extend its expertise for international clinical trials and the worldwide regulatory ecosystem. 

Care Access CEO and co-founder Ahmad Namvargolian said: “We’re on a path to achieve dramatically better and faster results for global clinical trials, with the intention to accelerate the approval process of new therapies and to bring more treatment options to healthcare. 

“Our mission is to bring to life the future of clinical research, and IBPClin shares our vision to bring our unique DCT model to Latin America.”